-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Risankizumab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risankizumab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risankizumab in Atopic Dermatitis (Atopic Eczema) Drug Details: Risankizumab (Skyrizi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risankizumab in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risankizumab in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risankizumab in Ulcerative Colitis Drug Details: Risankizumab (Skyrizi) is a humanized...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belimumab in Cryoglobulinemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belimumab in Cryoglobulinemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belimumab in Cryoglobulinemia Drug Details: Belimumab (Benlysta) is a human IgG1 monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belimumab in Emphysema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belimumab in Emphysema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belimumab in Emphysema Drug Details: Belimumab (Benlysta) is a human IgG1 monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belimumab in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belimumab in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belimumab in Systemic Sclerosis (Scleroderma) Drug Details: Belimumab (Benlysta) is...
-
Sector Analysis
Americas eGaming Market – Latest Developments, Telco Value Propositions and Monetization
Americas eGaming Market Report Overview The video game industry is still growing and evolving owing to technical innovation. The emergence of non-conventional distribution channels (e.g., cloud gaming) and changing consumer demands such as eSports and in-app micro-transactions have also revolutionized the industry. Furthermore, technologies such as AR/VR, cloud, and 5G are expected to drive innovation in the gaming industry and propel penetration in emerging markets. Buy the Full Report for More Insights into the Americas eGaming Market Download a Free...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Alopecia Areata report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Alopecia Areata Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Vitiligo Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Hidradenitis Suppurativa Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis Drug...